Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation and Depletion: 2021-2024

Historic Depreciation and Depletion for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $29,000.

  • ARS Pharmaceuticals' Depreciation and Depletion rose 141.67% to $29,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $79,000, marking a year-over-year increase of 8.22%. This contributed to the annual value of $79,000 for FY2024, which is 8.22% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $29,000 for Q4 2024, which was up 38.10% from $21,000 recorded in Q3 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Depreciation and Depletion peaked at $209,000 during Q2 2021, and registered a low of -$37,000 during Q2 2022.
  • In the last 3 years, ARS Pharmaceuticals' Depreciation and Depletion had a median value of $19,000 in 2023 and averaged $15,500.
  • In the last 5 years, ARS Pharmaceuticals' Depreciation and Depletion slumped by 117.70% in 2022 and then soared by 200.00% in 2023.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' Depreciation and Depletion stood at $204,000 in 2021, then tumbled by 93.14% to $14,000 in 2022, then decreased by 14.29% to $12,000 in 2023, then skyrocketed by 141.67% to $29,000 in 2024.
  • Its last three reported values are $29,000 in Q4 2024, $21,000 for Q3 2024, and $18,000 during Q2 2024.